课题基金 / 基金详情

Mobile brain sensing platform for detection of opioid craving and treatment response

Mobile brain sensing platform for detection of opioid craving and treatment response
用于检测阿片类药物渴望和治疗反应的移动大脑传感平台
批准号:
10264121
负责人:
Scott Burwell
金额:
$11.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-15 至 2023-02-28

项目摘要

项目成果

Scott Burwell的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要/摘要 意义:超过200万美国人患有阿片类药物使用障碍(OUD)并在治疗后复发 超过60%,强调需要了解在OUD干预中什么是“有效的”(以及什么是不有效的)。 目前,没有标准化的、客观的护理点工具来通知治疗提供者患者的 阿片类药物渴求程度和复发易感性,留下主观和不清楚的治疗效果 减少饥饿感,防止复发。这些不足导致了代价高昂的长期循环。 复发、急诊室就诊、法律问题、再次入院治疗、过量用药和可能的死亡 OUD患者所经历的。创新:使用消费级移动脑电(EEG) 耳机和专有软件,Neurotype Inc.建议开发和商业化 NeuromarkR™,一个护理点脑感知平台,能够检测脑电线索反应性相关 毒品渴求和毒品使用和复发的预期指标。NeuromarkR可用于EEG的非 专家(例如,临床医生、技术人员)量化阿片类药物渴求的生物标记物相关性,基准治疗 有效性,并有可能为治疗决策提供参考。NeuromarkR平台:1)获取患者脑电 在观看情感(充满情感的)和阿片类药物相关的图像时,2)执行全自动脑电信号 处理和线索反应性量化,以及3)生成阿片类线索反应性的数字报告 可纵向测量以客观量化治疗终点的表型(例如,渴望 减少,改变药物线索反应性)。具体目标:SBIR一期项目有两个目标, 包括:1)渴求和脑电线索反应性表型的测量和纵向追踪 寻求治疗的患者超过48周的恢复,以及2)我们的NeuromarkR原型的开发 转变为可扩展的Web平台,以便在护理时生成临床洞察和报告。预期 结果:成功的项目成果包括:1)确定药物线索反应表型(例如,脑电 对阿片类药物线索的反应性,类似于脑电对自然奖励线索的反应性), 与康复结果相关(例如,治疗完成、长期戒酒、减少渴求),以及2) 一个成熟的网络平台,可以实现更广泛的临床和研究用途。最后,我们将获得反馈 来自关键利益相关者(例如,临床医生、患者),并发起与食品和药物管理局的Q-提交会议 行政当局将完善我们对第二阶段项目的监管计划。调查人员:我们的团队包括专家 在临床药物滥用治疗中,成瘾神经科学,脑电脑电监测,软件工程, 和健康技术初创公司的开发专业知识。
英文摘要
Project Summary/Abstract Significance: Over 2 million Americans have an Opioid Use Disorder (OUD) and relapse following treatment exceeds 60%, underlining a need to understand what “works” (and what does not) in OUD interventions. Currently, there are no standardized, objective point of care tools to inform treatment providers of patients’ level of opioid craving and relapse vulnerability, leaving subjective and unclear a treatment’s effectiveness on reducing craving and protecting against relapse. Such inadequacies contribute to the costly and chronic cycle of relapse, emergency room visits, legal problems, treatment re-admittance, overdose, and possible death experienced by OUD patients. Innovation: Using consumer-grade mobile electroencephalogram (EEG) headsets and proprietary software, Neurotype Inc. proposes development and commercialization of NeuromarkR™, a point of care brain-sensing platform that enables detection of EEG cue reactivity correlates of drug craving and prospective indicators of drug use and relapse. NeuromarkR may be used by EEG non- experts (e.g., clinicians, technicians) to quantify biomarker correlates of opioid craving, benchmark treatment effectiveness, and potentially inform treatment decisions. The NeuromarkR platform: 1) acquires patients’ EEG during viewing of affective (emotion-laden) and opioid-related images, 2) performs fully-automated EEG signal processing and cue reactivity quantification, and 3) generates a digital report of opioid cue reactivity phenotypes which can be measured longitudinally to objectively quantify treatment endpoints (e.g., craving reduction, change in drug cue reactivity). Specific aims: There are two aims of this SBIR Phase I project, including: 1) measurement and longitudinal tracking of craving and EEG cue reactivity phenotypes in treatment-seeking OUD patients over 48 weeks of recovery, and 2) development of our NeuromarkR prototype into a scalable web platform for generating clinical insights and reports at the point of care. Expected outcome: Successful project outcomes include: 1) identification of drug cue reactivity phenotypes (e.g., EEG reactivity to opioid cues that resembles EEG reactivity to naturally rewarding cues) in OUD patients that correlate with recovery outcomes (e.g., treatment completion, prolonged abstinence, reduced craving), and 2) an established web platform that enables broader clinical and research use. Finally, we will obtain feedback from crucial stakeholders (e.g., clinicians, patients) and initiate Q-Submission meetings with the Food and Drug Administration to refine our regulatory plan for the Phase II project. Investigators: Our team includes experts in clinical substance abuse treatment, addiction neuroscience, EEG brain monitoring, software engineering, and health technology startup development expertise.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Closed-loop attention bias modification brain training for opioid use disorder
  • 批准号:
    10699099
  • 项目类别:
  • 资助金额:
    $32.67万
  • 财政年份:
    2023
  • 负责人:
    Scott Burwell
  • 依托单位:
Cue-induced drug craving monitoring for opioid use disorder with visual evoked potentials
  • 批准号:
    10787065
  • 项目类别:
  • 资助金额:
    $32.9万
  • 财政年份:
    2023
  • 负责人:
    Scott Burwell
  • 依托单位:
Mobile brain sensing platform for detection of opioid craving and treatment response
  • 批准号:
    10158211
  • 项目类别:
  • 资助金额:
    $23.51万
  • 财政年份:
    2020
  • 负责人:
    Scott Burwell
  • 依托单位:
Mobile brain sensing platform for detection of opioid craving and treatment response
  • 批准号:
    10304771
  • 项目类别:
  • 资助金额:
    $5.49万
  • 财政年份:
    2020
  • 负责人:
    Scott Burwell
  • 依托单位:
海外基金